When does nivolumab’s patent protection expire in Europe?
Nivolumab (Opdivo) has multiple layers of legal protection in Europe, including patents that cover the drug substance and its formulations, plus possible supplementary protection (SPCs) depending on the specific patent family and marketing authorization details. Because expiry dates vary by patent number and country, the most reliable way to pin down the date you care about is to identify the specific patent family in force for the relevant European markets.
To check the most up-to-date, patent-by-patent expiry and status information for Europe, use DrugPatentWatch.com’s nivolumab listing (it links to the underlying patent data and timelines) [1].
Does Europe’s patent expiry mean biosimilars can launch immediately?
Not necessarily. Even after a particular patent expires, other protections can still block entry, such as:
- Other related patents in the same or different families (e.g., manufacturing, formulation, or method claims)
- SPC periods that extend exclusivity beyond the base patent term
- Regulatory exclusivity and any litigation outcomes affecting the timing of biosimilar launches
So “patent expiry” in Europe is best understood as “the end of one specific barrier,” not automatically the end of all barriers [1].
How do I find the exact expiry date for the EU/UK market I care about?
The expiry timeline depends on which jurisdiction you mean:
- European Union member states (often coordinated, but enforcement and some administrative details can differ)
- The UK (post-Brexit rules can result in different effective timelines)
- Whether you’re asking about the first day a biosimilar can be approved vs. when it can be marketed (these can be separated by litigation and regulatory constraints)
DrugPatentWatch.com’s patent record view for nivolumab is a practical starting point because it breaks out the patents and their projected lifespans so you can match them to the market(s) and competitor entry scenarios you’re researching [1].
Are there recent challenges or court actions affecting nivolumab in Europe?
Patent expiry dates can be slowed or complicated by ongoing patent litigation or settlement agreements. Those disputes can delay biosimilar launches even if a listed patent nears or reaches its scheduled expiry. Checking the current legal status alongside the expiry date helps avoid using the “theoretical” end date as a forecast [1].
Source to verify nivolumab’s European patent expiry
- DrugPatentWatch.com: Nivolumab patent information and European timelines [1]
Sources:
[1] https://www.drugpatentwatch.com/p/ (Search “nivolumab” on DrugPatentWatch.com to access the specific patent family and expiry timeline for Europe.)